Biogen News and Research

RSS

Brain-protecting immune cells may actually drive Alzheimer's disease

Immune cells that normally protect the body from damage by attacking foreign or infected cells are found in the brains of patients with Alzheimer's disease and related disorders at much higher levels than in healthy brains.

3 Sep 2026

Study reveals high prevalence of chronic traumatic encephalopathy among former NFL players

At minimum, nearly a quarter of all former National Football League (NFL) players who died from 2016 to 2021 had confirmed chronic traumatic encephalopathy (CTE) – a neurodegenerative disease linked to repeated head impacts – at death, finds a study published by The BMJ today.

25 Aug 2026

Severe mental illness may accelerate dementia and stroke vulnerability

People living with severe mental illness face a substantially higher risk of dementia throughout adulthood, as well as a significantly elevated risk of stroke in early and middle adulthood, according to a large new study based on health records from Catalonia, Spain.

17 Aug 2026

Modern blood thinners slow cognitive decline in Alzheimer's patients

People with both atrial fibrillation and Alzheimer's disease who are treated with modern NOAC blood-thinning medicines may experience a slower rate of cognitive decline.

12 Aug 2026

New blood protein biomarkers estimate timing of ALS symptoms

Months to several years before amyotrophic lateral sclerosis (ALS) symptoms arise, levels of certain blood proteins may dramatically shift.

27 Jul 2026

Multiple sclerosis mortality trends underscore need for comprehensive patient care

An analysis of more than 42,000 U.S. deaths linked to multiple sclerosis (MS) found that death rates varied by age, geography, and race and ethnicity, with Black patients dying younger than white patients and high blood pressure emerging as a growing contributor.

22 Jul 2026

Designing the AI-Enabled Life Sciences Workforce Summit Europe

AI's impact on drug discovery and manufacturing raises critical workforce questions, driving life sciences organizations to rethink skills and leadership.

From Designing the AI-Enabled Life Sciences Workforce Summit Europe 15 Jul 2026

Study sheds light on the prognostic value of blood test for predicting cognitive impairment risk

A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged around the extent to which such tests can accurately predict whether a cognitively healthy individual will go on to develop cognitive impairment-a key symptom of Alzheimer's disease.

15 Jul 2026

New artificial intelligence model reveals invisible multiple sclerosis lesions

One of the uncomfortable truths about multiple sclerosis is that the part of the brain likely to reveal the most about the disease and how a patient will be impacted has been mostly invisible to clinicians.

7 Jul 2026

Large study uncovers brain network differences in bipolar disorder

New research from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has discovered subtle but widespread differences in the brain's communication networks in people with bipolar disorder, offering new insight into how illness severity and treatment may relate to brain wiring.

9 Jun 2026

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

5 Jun 2026

Antibody fragment offers safer alternative for Alzheimer disease treatment

In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).

5 Jun 2026

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.

28 May 2026

Three cognitive trajectories identified in preclinical Alzheimer’s disease

Cognitive decline in Alzheimer's disease differs substantially from one person to the next and is not well predicted by existing medical tests.

27 Apr 2026

US Medicaid data finds buprenorphine safe for long-term child development

Children born to mothers who used buprenorphine for opioid addiction during pregnancy do not have a greater risk of neurodevelopmental disorders, such as ADHD and autism, compared with children whose mothers took methadone, finds a large US study published by The BMJ today.

17 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026

The FDA has released draft guidance for NAMs Validation – Now what?

On March 18th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro models (CIVMs).

From Hanson Wade Group - 11th 3D Tissue Models Summit 2026 9 Apr 2026

Investigational oral therapy shows safety and potential benefits in ALS trial

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits.

16 Mar 2026

Older Americans willing to travel farther for medical care

Older Americans are willing to travel far for medical care - sometimes much farther than policymakers and experts assume, according to researchers at the USC Dornsife College of Letters, Arts and Sciences.

13 Mar 2026

Study links p-tau217 levels to long-term dementia risk in women

Researchers from the University of California San Diego have found that a novel blood-based biomarker can predict a woman's risk of developing dementia as many as 25 years before symptoms appear.

10 Mar 2026